Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand
– Submission to New Zealand’s Medsafe marks the first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in New Zealand – All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for Medsafe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today…